Molidustat Sodium

莫立司他钠

Report date: 2026/02/02 10:51:02
NME

Base Information

Drug NameMolidustat Sodium
Drug Alias NameHIF-PH inhibitor - Bayer莫立司他Hypoxia-inducible factor-prolyl hydroxylase inhibitor莫度司他molidustat +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHypoxia-inducible factor prolyl hydroxylase inhibitors
TargetsHypoxia-inducible factor prolyl hydroxylase
Therapy Area/IndicationsAnemiaRenal Insufficiency, ChronicKidney Diseases
Global Approved IndicationsAnemiaRenal Insufficiency, Chronic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2021/01/22
Country/TerritoryBulgariaUnited StatesPoland +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaIND
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesBayer Schering Pharma Ag Spółka Akcyjna Oddział W PolsceBayer AGBayer Healthcare Company Ltd
Inactive CompaniesN/A
Active IndicationsAnemiaRenal Insufficiency, Chronic
Inactive IndicationsKidney Diseases

Other Information

ATC CodeB03XA
Related LinksWikipediaDrugBankKEGG